AXXAM

info@axxam.com

Webinar

Drug Discovery for Metabolic Disorders – More than Gut Feeling

This webinar is now on demand!
Fill the form below to receive webinar video link directly to your inbox.

    About the Webinar:

    The widespread prevalence of metabolic disease and its cardiovascular and other health consequences constitute a major health burden. By improving clinical outcomes in these patients, the incretin mimetics have positioned themselves as the next generation of mega-blockbuster drugs and reinvigorated interest in the field. 

    In our webinar, we will briefly recapitulate the evolution of this research area and introduce Axxam’s specific offerings to support drug research in metabolic dysfunction. In addition, we will provide insights into our compound profiling activities supporting hit or lead optimization programs of our clients. These activities include the in-depth pharmacological characterization of drug-receptor interactions, including allostery, biased signalling and more.

    In this webinar you will learn about:

    • Incretin mimetics for the treatment of metabolic disorders
    • Axxam’s bioassays and compound libraries supporting metabolism drug discovery research
    • Pharmacological compound profiling at Axxam

    Keywords:

    Metabolic disorders; GLP1; enteroendocrine cells; incretins; hormones; GPCRs; transporters; cell-based assays; Drug Discovery.

    Speakers:

    • Jörg Hüser , CSO – Axxam

    • Alberto Di Silvio , Head, Compound Profiling – Axxam

    Jörg Hüser studied Biology at the Ruhr-University in Bochum, Germany. He received a PhD in Physiology working on excitation-contraction coupling in cardiac muscle cells. Following a postdoctoral training at Loyola University in Chicago, Stritch School of Medicine, in Maywood, IL, USA, he joined Bayer AG’s Pharma Research in Wuppertal, Germany. During his almost 25 year tenure at Bayer, he held different management positions, leading research units in Lead Discovery and Heart & Vascular Disease Research. In June 2023 he joined Axxam as Chief Scientific Officer.

    Alberto Di Silvio has a degree in biological Sciences (1998, Università degli studi di Milano). He joined Axxam in 2002 and spent the first 4 years working in the cell biology group where he was responsible for the development of cell based-assays for different target classes, i.e. GPCRs, Ion Channels, NHRs. In 2006, Alberto moved into the newly created High-Throughput Screening group where he had the opportunity to acquire a huge experience in both HTS and compound profiling fields. After 13 years in HTS laboratories, in June 2019 he was appointed as Unit Manager of the Compound Profiling Unit with the responsibility of coordinating and supervising the activities of seven Principal Scientists all involved in compound profiling related projects. In January 2023, Alberto was nominated Head of the Compound Profiling Group within Axxam’s Lead Discovery Services department.

    Back
    Scroll to Top